INS and malignant colon neoplasm: We recently showed that both metformin and a novel insulin sensitizer, a controlled-release mitochondrial protonophore, slows tumor growth in two models of colon cancer, and that the tumor-slowing effects of both agents were dependent on reversal of hyperinsulinemia [21], demonstrating a causative role for hyperinsulinemia in these mouse models.